AbbVie (4AB) Stock Forecast & Price Target

Compare

23 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

4AB Analyst Ratings

Moderate Buy

10 Buy

6 Hold

0 Sell

Based on 16 analysts giving stock ratings to

AbbVie

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

4AB Stock 12 Month Forecast

Average Price Target

€188.41

▲(10.83%Upside)

Based on 16 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is €188.41 with a high forecast of €223.12 and a low forecast of €148.74. The average price target represents a 10.83% change from the last price of €170.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"147":"€147","224":"€224","166.25":"€166.3","185.5":"€185.5","204.75":"€204.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":223.11721995,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€223.12</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":188.4071802817,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€188.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":148.7448133,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€148.74</span>\n  </div></div>","useHTML":true}}],"tickPositions":[147,166.25,185.5,204.75,224],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,160.598,165.40717076538462,170.21634153076923,175.02551229615386,179.83468306153847,184.64385382692308,189.45302459230768,194.2621953576923,199.07136612307693,203.88053688846153,208.68970765384614,213.49887841923078,218.30804918461536,{"y":223.11721995,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,160.598,162.73716771397693,164.87633542795385,167.01550314193076,169.1546708559077,171.29383856988463,173.43300628386154,175.57217399783846,177.71134171181538,179.8505094257923,181.98967713976924,184.12884485374616,186.26801256772308,{"y":188.4071802817,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,160.598,159.6862164076923,158.7744328153846,157.86264922307694,156.95086563076924,156.03908203846154,155.12729844615384,154.21551485384617,153.30373126153847,152.39194766923077,151.48016407692307,150.5683804846154,149.6565968923077,{"y":148.7448133,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":152.457,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":170.051,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.503,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.155,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":183.051,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":168.202,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.458,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.591,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":194.211,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":191.166,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.934,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":160.995,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":160.598,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€223.12

Average Price Target€188.41

Lowest Price Target€148.74

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Vamil DivanGuggenheim

Guggenheim

€188.99

Buy

11.17%

Upside

Reiterated

07/22/25

Guggenheim Reaffirms Their Buy Rating on AbbVie (ABBV)

Geoff MeachamCiti

Citi

€179.37

Hold

5.51%

Upside

Reiterated

07/21/25

AbbVie (ABBV) Receives a Hold from Citi

Gary NachmanRaymond James

Raymond James

€166.75→€198.62

Buy

16.83%

Upside

Reiterated

07/17/25

Raymond James Sticks to Their Buy Rating for AbbVie (ABBV)

Luisa HectorBerenberg Bank

Berenberg Bank

€148.74

Hold

-12.50%

Downside

Reiterated

07/14/25

AbbVie (ABBV) Gets a Hold from Berenberg Bank

Unknown AnalystEvercore ISI

Not Ranked

Evercore ISI

€179.37

Buy

5.51%

Upside

Reiterated

07/11/25

SMID Biotech Week in Review

David RisingerLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

07/10/25

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Alkermes (NASDAQ: ALKS)

Terence FlynnMorgan Stanley

Morgan Stanley

€218.74

Buy

28.67%

Upside

Reiterated

07/10/25

AbbVie (ABBV) Receives a Buy from Morgan Stanley

Chris SchottJ.P. Morgan

J.P. Morgan

€174.99

Buy

2.94%

Upside

Reiterated

07/10/25

AbbVie: A Strong Buy with Promising Growth Prospects and Stable Outlook

Evan SeigermanBMO Capital

BMO Capital

€188.12

Buy

10.66%

Upside

Reiterated

07/09/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Mohit BansalWells Fargo

Wells Fargo

€209.99

Buy

23.53%

Upside

Reiterated

07/08/25

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Cigna (NYSE: CI) and Brookdale Senior Living (NYSE: BKD)

Courtney BreenBernstein

Bernstein

―

Hold

―

Reiterated

07/08/25

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Esperion (NASDAQ: ESPR)

Matt PhippsWilliam Blair

William Blair

―

Buy

―

Reiterated

06/30/25

AbbVie's Strategic Acquisition of Capstan Therapeutics: A High-Risk, High-Reward Move in Immunology

Asad HaiderGoldman Sachs

Goldman Sachs

€169.74→€172.37

Hold

1.39%

Upside

Reiterated

06/10/25

Balanced Outlook for AbbVie: Hold Rating Amid Opportunities and Challenges

Tim AndersonBank of America Securities

Bank of America Securities

€178.49

Hold

5.00%

Upside

Reiterated

06/06/25

Bank of America Securities Remains a Hold on AbbVie (ABBV)

Nico ChenDBS

DBS

€160.12

Hold

-5.81%

Downside

Reiterated

05/14/25

AbbVie Hold Rating: Balancing Growth in Immunology and Neuroscience Amidst Humira Challenges and Macroeconomic Uncertainties

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Vamil DivanGuggenheim

Guggenheim

€188.99

Buy

11.17%

Upside

Reiterated

07/22/25

Guggenheim Reaffirms Their Buy Rating on AbbVie (ABBV)

Geoff MeachamCiti

Citi

€179.37

Hold

5.51%

Upside

Reiterated

07/21/25

AbbVie (ABBV) Receives a Hold from Citi

Gary NachmanRaymond James

Raymond James

€166.75→€198.62

Buy

16.83%

Upside

Reiterated

07/17/25

Raymond James Sticks to Their Buy Rating for AbbVie (ABBV)

Luisa HectorBerenberg Bank

Berenberg Bank

€148.74

Hold

-12.50%

Downside

Reiterated

07/14/25

AbbVie (ABBV) Gets a Hold from Berenberg Bank

Unknown AnalystEvercore ISI

Not Ranked

Evercore ISI

€179.37

Buy

5.51%

Upside

Reiterated

07/11/25

SMID Biotech Week in Review

David RisingerLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

07/10/25

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Alkermes (NASDAQ: ALKS)

Terence FlynnMorgan Stanley

Morgan Stanley

€218.74

Buy

28.67%

Upside

Reiterated

07/10/25

AbbVie (ABBV) Receives a Buy from Morgan Stanley

Chris SchottJ.P. Morgan

J.P. Morgan

€174.99

Buy

2.94%

Upside

Reiterated

07/10/25

AbbVie: A Strong Buy with Promising Growth Prospects and Stable Outlook

Evan SeigermanBMO Capital

BMO Capital

€188.12

Buy

10.66%

Upside

Reiterated

07/09/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Mohit BansalWells Fargo

Wells Fargo

€209.99

Buy

23.53%

Upside

Reiterated

07/08/25

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Cigna (NYSE: CI) and Brookdale Senior Living (NYSE: BKD)

Courtney BreenBernstein

Bernstein

―

Hold

―

Reiterated

07/08/25

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Esperion (NASDAQ: ESPR)

Matt PhippsWilliam Blair

William Blair

―

Buy

―

Reiterated

06/30/25

AbbVie's Strategic Acquisition of Capstan Therapeutics: A High-Risk, High-Reward Move in Immunology

Asad HaiderGoldman Sachs

Goldman Sachs

€169.74→€172.37

Hold

1.39%

Upside

Reiterated

06/10/25

Balanced Outlook for AbbVie: Hold Rating Amid Opportunities and Challenges

Tim AndersonBank of America Securities

Bank of America Securities

€178.49

Hold

5.00%

Upside

Reiterated

06/06/25

Bank of America Securities Remains a Hold on AbbVie (ABBV)

Nico ChenDBS

DBS

€160.12

Hold

-5.81%

Downside

Reiterated

05/14/25

AbbVie Hold Rating: Balancing Growth in Immunology and Neuroscience Amidst Humira Challenges and Macroeconomic Uncertainties

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AbbVie

1 Month

xxx

Success Rate

14/22 ratings generated profit

Average Return

+1.81%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 63.64% of your transactions generating a profit, with an average return of +1.81% per trade.

3 Months

xxx

Success Rate

18/25 ratings generated profit

Average Return

+7.28%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 72.00% of your transactions generating a profit, with an average return of +7.28% per trade.

1 Year

Christopher RaymondPiper Sandler

Success Rate

38/41 ratings generated profit

Average Return

+22.28%

assigned a buy rating 6 months ago

Copying Christopher Raymond's trades and holding each position for 1 Year would result in 92.68% of your transactions generating a profit, with an average return of +22.28% per trade.

2 Years

xxx

Success Rate

40/41 ratings generated profit

Average Return

+39.20%

assigned a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 97.56% of your transactions generating a profit, with an average return of +39.20% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4AB Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 4AB has received 19 Buy Ratings, 23 Hold Ratings, and 0 Sell Ratings. 4AB average Analyst price target in the past 3 months is 188.41.

Each month's total comprises the sum of three months' worth of ratings.

4AB Financial Forecast

4AB Earnings Forecast

Next quarter’s earnings estimate for 4AB is €2.86 with a range of €2.72 to €2.97. The previous quarter’s EPS was €2.60. 4AB beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.18% of the time in the same period. In the last calendar year 4AB has Preformed in-line its overall industry.

4AB Sales Forecast

Next quarter’s sales forecast for 4AB is €13.61B with a range of €13.24B to €14.00B. The previous quarter’s sales results were €13.52B. 4AB beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.35% of the time in the same period. In the last calendar year 4AB has Preformed in-line its overall industry.

4AB Stock Forecast FAQ

What is DE:4AB’s average 12-month price target, according to analysts?

Based on analyst ratings, AbbVie’s 12-month average price target is 188.41.

What is DE:4AB’s upside potential, based on the analysts’ average price target?

AbbVie has 10.83% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AbbVie a Buy, Sell or Hold?

AbbVie has a consensus rating of Moderate Buy, which is based on 10 buy ratings, 6 hold ratings and 0 sell ratings.

What is AbbVie’s share price target?

The average share price target for AbbVie is 188.41. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €223.12 ,and the lowest forecast is €148.74. The average share price target represents 10.83% Increase from the current price of €170.

What do analysts say about AbbVie?

AbbVie’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of AbbVie?

To buy shares of DE:4AB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

AbbVie (4AB) Stock Forecast & Price Target

4AB Analyst Ratings

4AB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AbbVie

4AB Analyst Recommendation Trends

4AB Financial Forecast

4AB Earnings Forecast

4AB Sales Forecast

4AB Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts